- Home
- LUCY vs NXTC Comparison
LUCY vs NXTC Comparison
Compare LUCY & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- NXTC
- Stock Information
- Founded
- LUCY 2017
- NXTC 2015
- Country
- LUCY United States
- NXTC United States
- Employees
- LUCY N/A
- NXTC N/A
- Industry
- LUCY Ophthalmic Goods
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- NXTC Health Care
- Exchange
- LUCY Nasdaq
- NXTC Nasdaq
- Market Cap
- LUCY 10.3M
- NXTC 9.3M
- IPO Year
- LUCY 2022
- NXTC 2019
- Fundamental
- Price
- LUCY $1.81
- NXTC $0.40
- Analyst Decision
- LUCY
- NXTC Strong Buy
- Analyst Count
- LUCY 0
- NXTC 2
- Target Price
- LUCY N/A
- NXTC $3.50
- AVG Volume (30 Days)
- LUCY 1.0M
- NXTC 241.6K
- Earning Date
- LUCY 05-20-2025
- NXTC 05-01-2025
- Dividend Yield
- LUCY N/A
- NXTC N/A
- EPS Growth
- LUCY N/A
- NXTC N/A
- EPS
- LUCY N/A
- NXTC N/A
- Revenue
- LUCY $1,636,440.00
- NXTC N/A
- Revenue This Year
- LUCY $542.00
- NXTC N/A
- Revenue Next Year
- LUCY $148.54
- NXTC N/A
- P/E Ratio
- LUCY N/A
- NXTC N/A
- Revenue Growth
- LUCY 41.99
- NXTC N/A
- 52 Week Low
- LUCY $1.57
- NXTC $0.22
- 52 Week High
- LUCY $27.20
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- LUCY 41.79
- NXTC 47.10
- Support Level
- LUCY $1.70
- NXTC $0.34
- Resistance Level
- LUCY $1.85
- NXTC $0.52
- Average True Range (ATR)
- LUCY 0.20
- NXTC 0.06
- MACD
- LUCY 0.05
- NXTC 0.01
- Stochastic Oscillator
- LUCY 20.11
- NXTC 45.14
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.